Kalshi Inc. and Polymarket are slinging weighty accusations at each other as the prediction market rivalry heats up and the nascent industry comes under intense scrutiny in Washington. While the platforms have sparred frequently in the past, the rhetoric has escalated in recent days after Kalshi launched a pointed advertising campaign and its employees publicly criticized Polymarket. “Polymarket’s...
Kalshi Inc. and Polymarket are slinging weighty accusations at each other as the prediction market rivalry heats up and the nascent industry comes under intense scrutiny in Washington. While the platforms have sparred frequently in the past, the rhetoric has escalated in recent days after Kalshi launched a pointed advertising campaign and its employees publicly criticized Polymarket. “Polymarket’s irresponsible, dangerous, and illegal behavior threatens legal American prediction markets,” Benjamin Freeman, who works on political and election markets at Kalshi, wrote in a social media post on Monday. The accusations quickly sparked a heated back-and-forth between the companies. “We welcome competition, but believe the discussion should be grounded in facts. Misinforming the public only harms the industry as a whole and participants,” Polymarket said in a statement. Elisabeth Diana, a spokesperson for Kalshi, responded: “That’s laughable, coming from a company whose majority of trading volume is offshore and unregulated, and whose policies allow death markets.” The feuding comes as Polymarket and Kalshi battle for leadership of the fast-growing prediction market industry, which has opened up a new way for Americans to wager on everything from sports to elections. The startups have both registered one record trading week after another, with nearly $6 billion in notional trading volume between them in recent weeks, according to user-compiled data on Dune Analytics. Differences in how the exchanges are set up and operate are at the heart of the dispute. Kalshi’s platform is based in the US and overseen by the Commodity Futures Trading Commission, while Polymarket’s primary exchange operates offshore. Polymarket has used its operations outside the US to list contracts tied to military conflict — including the war in Iran — which Kalshi has said are unethical and illegal. “We don’t do death markets,” one of Kalshi’s ads reads. Read More: Iran Strikes Expose Dark Edge Case ...
Taitai6769/iStock via Getty Images Nucor ( NUE ) and Commercial Metals ( CMC ) both rise 2.7% in Wednesday's trading as Goldman Sachs started coverage with Buy ratings and respective $210 and $74 price targets, expecting U.S. steel shipments to rise as a result of declining imports due to tariffs, as U.S. producers increase volumes to compensate for the lack of international steel imports. The ban...
Taitai6769/iStock via Getty Images Nucor ( NUE ) and Commercial Metals ( CMC ) both rise 2.7% in Wednesday's trading as Goldman Sachs started coverage with Buy ratings and respective $210 and $74 price targets, expecting U.S. steel shipments to rise as a result of declining imports due to tariffs, as U.S. producers increase volumes to compensate for the lack of international steel imports. The bank said it expects U.S. steel shipment growth will outpace demand growth in 2026, while volume growth for domestic shipments is still greater than import volume growth in 2027 before moderating in 2028. The current steel price environment should act as a tailwind for all producers with metal price exposure, but given the recent pullback as a result of inflation and global growth fears, Goldman's Nick Cash and Cecilia Tang see current prices providing an attractive entry point for select U.S. steel equities, particularly Nucor ( NUE ) and Commercial Metals ( CMC ). Goldman's Buy rating on Nucor ( NUE ) is supported by three key factors: the company is poised to outperform the U.S. steel market through rising end-market demand, import share gains, and growth-related volume expansion via its West Virginia mill; structural cost advantages that should drive margin expansion; and a transition from heavy capital investment to a free cash flow harvesting phase. Cash and Tang said Commercial Metals ( CMC ) is a Buy because of strong North America end-market demand with exposure to U.S. regions with above-average growth; inorganic and organic margin expansion and growth position the company well ahead of the cycle; and a strategic focus on prioritizing balance sheet health and cash flow generation over immediate capital returns. The analysts took a Neutral view on Cleveland-Cliffs ( CLF ), citing caution on the high fixed cost structure of the business as steel prices likely have posted near-term highs. More on Nucor and Commercial Metals Nucor: Tariff Turmoil Is Why You Stick With Hi...
Sandhya Venkatachalam, founder of Axiom Partners, joins Dani Burger on "Bloomberg Deals." They discuss how venture capital is addressing the rising valuations tied to AI businesses. (Source: Bloomberg)
Sandhya Venkatachalam, founder of Axiom Partners, joins Dani Burger on "Bloomberg Deals." They discuss how venture capital is addressing the rising valuations tied to AI businesses. (Source: Bloomberg)
quantic69/iStock via Getty Images The last time I wrote about United Therapeutics Corporation ( UTHR ) it was in a Seeking Alpha article entitled " United Therapeutics: Nebulized Tyvaso Label Expansion Possible For IPF After Study Win ." With respect to this article, I mentioned that the company was able to achieve positive results from its phase 3 TETON-2 study using nebulized Tyvaso for the trea...
quantic69/iStock via Getty Images The last time I wrote about United Therapeutics Corporation ( UTHR ) it was in a Seeking Alpha article entitled " United Therapeutics: Nebulized Tyvaso Label Expansion Possible For IPF After Study Win ." With respect to this article, I mentioned that the company was able to achieve positive results from its phase 3 TETON-2 study using nebulized Tyvaso for the treatment of patients with idiopathic pulmonary fibrosis [IPF]. Specifically, the primary endpoint of change in absolute Forced Vital Capacity [FVC] from baseline to week 52 was met in favor of Tyvaso in a statistically significant manner. I had a Strong Buy rating, and today I'm going to stick to it because of what just happened. The company was able to achieve another win with respect to the development of this IPF treatment program. A few days ago on March 30, 2026, it noted that it had also achieved positive results from its phase 3 TETON-1 study using Tyvaso to treat patients with IPF. What makes this study a huge win compared to the last one is that there was an even better effect on improving absolute [FVC] in this trial. Plus, this study was the one that recruited patients from the United States and Canada. Why the continued Strong Buy rating? That's because now this company has positive data from both TETON-1 and TETON-2 to seek supplemental New Drug Application [sNDA] approval of Tyvaso for the treatment of patients with IPF. Speaking of which, as an update, it believes it is on track to submit such a regulatory application for approval of this IPF indication by the end of this summer. Even better, it is going to seek Priority Review as well, which could speed up the review time. Lastly, the company is already in the process of an expansion opportunity. It is also currently evaluating the use of Tyvaso in the ongoing phase 3 TETON-PPF for the treatment of patients with progressive pulmonary fibrosis [PPF]. With its second phase 3 study win of Tyvaso for the treatment ...
Former FTX engineering chief Nishad Singh will have to return $3.7 million in illegal profits under a settlement with the US derivatives regulator over his role at the collapsed cryptocurrency exchange. Singh will also be banned from trading for five years and prohibited from registering with the regulator for eight years, the Commodity Futures Trading Commission said in a statement on Wednesday. ...
Former FTX engineering chief Nishad Singh will have to return $3.7 million in illegal profits under a settlement with the US derivatives regulator over his role at the collapsed cryptocurrency exchange. Singh will also be banned from trading for five years and prohibited from registering with the regulator for eight years, the Commodity Futures Trading Commission said in a statement on Wednesday. The agency said it didn’t seek a monetary penalty or restitution based on his cooperation in the investigation. “The injunctions and monetary relief imposed here demonstrate the significant benefits that may be achieved through cooperating with the CFTC,” Enforcement Director David Miller said. A spokesperson for Singh didn’t immediately respond to a request for comment. The former FTX engineering chief pleaded guilty to fraud in 2023 as part of a deal with federal prosecutors and later avoided prison time . He was one of the top executives who testified against Sam Bankman-Fried , the co-founder of the once high-flying crypto exchange that imploded in 2022. Bankman-Fried is currently serving a 25-year prison sentence. He filed a long-shot request earlier this year for a new trial.
sankai/iStock via Getty Images Individual investors’ allocations to cash increased while stock and bond allocations decreased in the March AAII Asset Allocation Survey. Stock and stock fund allocations decreased 0.2 percentage points to 69.2%. Stock and stock fund allocations are above their historical average of 61.5% for the 70th consecutive month. Bond and bond fund allocations decreased 0.6 pe...
sankai/iStock via Getty Images Individual investors’ allocations to cash increased while stock and bond allocations decreased in the March AAII Asset Allocation Survey. Stock and stock fund allocations decreased 0.2 percentage points to 69.2%. Stock and stock fund allocations are above their historical average of 61.5% for the 70th consecutive month. Bond and bond fund allocations decreased 0.6 percentage points to 15.8%. Bond and bond fund allocations are below their historical average of 16.0% for the fifth time in six months. Cash allocations increased 0.8 percentage points to 15.0%. Cash allocations are below their historical average of 22.5% for the 40th consecutive month. March AAII Asset Allocation Survey results: Stocks and Stock Funds: 69.2%, down 0.2 percentage points Bonds and Bond Funds: 15.8%, down 0.6 percentage points Cash: 15.0%, up 0.8 percentage points March AAII Asset Allocation Survey details: Stocks: 29.5%, down 1.3 percentage points Stock Funds: 39.7%, up 1.0 percentage points Bonds: 5.1%, down 0.1 percentage points Bond Funds: 10.7%, down 0.5 percentage points Historical averages: Stocks/Stock Funds: 61.5% Bonds/Bond Funds: 16.0% Cash: 22.5% The AAII Asset Allocation Survey has been conducted monthly since November 1987 and asks AAII members what percentage of their portfolios are allocated to stocks, stock funds, bonds, bond funds and cash.
A lot of people look forward to turning 65 because that's when Medicare eligibility generally starts. But it's not a given that you'll want to enroll in Medicare at age 65. It may be that you're still working at 65 or have health insurance through a spouse's workplace plan. At that point, why enroll in Medicare -- and pay for it -- when you're happy with your coverage? Image source: Getty Images. ...
A lot of people look forward to turning 65 because that's when Medicare eligibility generally starts. But it's not a given that you'll want to enroll in Medicare at age 65. It may be that you're still working at 65 or have health insurance through a spouse's workplace plan. At that point, why enroll in Medicare -- and pay for it -- when you're happy with your coverage? Image source: Getty Images. Continue reading
Marvell Technology (NASDAQ:MRVL) shares are up 7% in Wednesday trading, climbing above $106 after opening at $99.05. The catalyst is unmistakable: NVIDIA‘s (NASDAQ:NVDA) $2 billion strategic investment in Marvell, integrating the company into the NVIDIA AI factory and AI-RAN ecosystem through NVLink Fusion. The move puts Marvell squarely at the center of the AI infrastructure ... Marvell Technolog...
Marvell Technology (NASDAQ:MRVL) shares are up 7% in Wednesday trading, climbing above $106 after opening at $99.05. The catalyst is unmistakable: NVIDIA‘s (NASDAQ:NVDA) $2 billion strategic investment in Marvell, integrating the company into the NVIDIA AI factory and AI-RAN ecosystem through NVLink Fusion. The move puts Marvell squarely at the center of the AI infrastructure ... Marvell Technology Rises 7%: The NVIDIA NVLink Deal Is Turning This Chip Stock Into an AI Powerhouse
Totojang/iStock via Getty Images Grail ( GRAL ) and preventative health platform Superpower are partnering for the latter to provide the former's Galleri multi-cancer early detection test. The test can detect a signal found in more than 50 cancer types. It can also predict a cancer's signal origin. Grail's PATHFINDER-2 study found that adding Galleri to recommended cancer screenings boosted cancer...
Totojang/iStock via Getty Images Grail ( GRAL ) and preventative health platform Superpower are partnering for the latter to provide the former's Galleri multi-cancer early detection test. The test can detect a signal found in more than 50 cancer types. It can also predict a cancer's signal origin. Grail's PATHFINDER-2 study found that adding Galleri to recommended cancer screenings boosted cancer detection more than seven-fold. More on GRAIL, Inc. An Early Cancer Detection Test, Put To The Test GRAIL: The NHS-Galleri Setback - I Would Wait For Low $30s To Buy (Rating Downgrade) GRAIL: A Major Trial Disappointment Grail upgraded at TD Cowen; says selloff is buying opportunity GRAIL announces leadership transition
Jakub Zerdzicki/iStock via Getty Images Reserve Management Purchases At the Press Briefing following the December 2025 FOMC meeting, Chair Powell made an announcement that the Fed would begin purchasing shorter-term Treasury securities to maintain an ample supply of reserves. The move was surprising because the Fed had just halted their Quantitative Tightening Program, effective December 1 st . So...
Jakub Zerdzicki/iStock via Getty Images Reserve Management Purchases At the Press Briefing following the December 2025 FOMC meeting, Chair Powell made an announcement that the Fed would begin purchasing shorter-term Treasury securities to maintain an ample supply of reserves. The move was surprising because the Fed had just halted their Quantitative Tightening Program, effective December 1 st . Some surmised that the Fed was resuming Quantitative Easing. Chair Powell, however, was firm in his statement that “these issues are separate from -and have no implications for-the stance of monetary policy.” Chair Powell added that the Reserve Management Purchases (RMPs) would be seasonal and would occur during the natural decline in reserves until Tax Day on April 15 th . After that, RMPs would be reduced to what was needed to meet the secular growth in the Fed’s balance sheet. How Reserve Management Purchases Have Been Working It has been almost four months since the Fed began RMPs. Roberto Perli, the Manager of the System Open Market Account, gave an update on the program recently before the Money Marketeers of NYU. In his presentation, Manager Perli was quite expansive on the nuts and bolts of the program. Perli explained how RMPs came about. His responsibility is to oversee the implementation of monetary policy at the Open Market Trading Desk (the Desk), and to keep the FOMC informed about financial market developments. Since the Fed began their Policy Normalization program in 1Q22, they have been watching the level of Bank Reserves. While the Fed has been reducing their security holdings through runoffs, their goal has been to reduce the liquidity they had injected during Quantitative Easing. The Fed has never been precise about how much QT they would do; they simply stated they would continue to “implement monetary policy efficiently and effectively in an ample reserves regime.” It was Perli’s job to determine when reserves reached ample. The liquidity the Fed injecte...
Just_Super/E+ via Getty Images Tempus AI ( TEM ) is one of the most defensible data platforms in AI-driven healthcare that serves about half of U.S. oncologists through the combination of its proprietary multimodal clinical dataset and its next-generation sequencing (NGS) diagnostics engine. The stock has fallen sharply since reaching its peak in November last year, owing to the excessive optimism...
Just_Super/E+ via Getty Images Tempus AI ( TEM ) is one of the most defensible data platforms in AI-driven healthcare that serves about half of U.S. oncologists through the combination of its proprietary multimodal clinical dataset and its next-generation sequencing (NGS) diagnostics engine. The stock has fallen sharply since reaching its peak in November last year, owing to the excessive optimism that was priced into the stock at that time, when it traded at 15x forward revenue. With valuations settling down to 5.4x EV/sales, we believe it creates a compelling entry point for the AI-native precision-medicine platform. Data by YCharts A self-reinforcing business model TEM operates through two interdependent segments. In FY2025, Genomics contributed to 75% of total revenue, or $955M, which encompasses NGS diagnostics, including xT (comprehensive tumor profiling), xF (liquid biopsy), xR (RNA-based therapy selection), xM (MRD monitoring), and hereditary testing. This segment is the data generation engine part of the flywheel. During the same period, Data & Services was 25% of total revenue of $316M. Its Insights platform has been licensing de-identified multimodal datasets to 19 out of the top 20 global pharmaceuticals. It also conducts a clinical trial matching service via its Trials platform. Structurally, the two segments are self-reinforcing in that each Genomics test creates a de-identified patient record that feeds into the Insights library. This builds up a robust dataset that gets more valuable over time, while being difficult to replicate. A competitive positioning Representing about one-fifth of the U.S. economy, healthcare is a $4.9T industry, but only accounts for 12% of total software spend. However, things have changed with the onset of AI, as the industry is now deploying AI at more than 2.2x the rate of the broader economy, according to Menlo Ventures . Tempus' core domain is in precision oncology, which is experiencing a multi-decade secular shift driv...
Jonathan Kitchen Large-cap stocks are under selling pressure, but this RSI screen flags the most oversold giants across health care, staples, and real estate as potential value plays. Below is a list of the top 10 large-cap stocks ranked by their Relative Strength Index ( RSI ), representing various sectors including Health Care, Consumer Staples, and Real Estate. The list includes stocks with mar...
Jonathan Kitchen Large-cap stocks are under selling pressure, but this RSI screen flags the most oversold giants across health care, staples, and real estate as potential value plays. Below is a list of the top 10 large-cap stocks ranked by their Relative Strength Index ( RSI ), representing various sectors including Health Care, Consumer Staples, and Real Estate. The list includes stocks with market capitalizations of $10B or more, ranked from most oversold to least oversold. The list is topped by Sysco Corporation ( SYY ), with an RSI of 24, followed by Boston Scientific Corporation ( BSX ) at 25. These two stocks are showing significant oversold signals. McCormick & Company ( MKC ), Cintas Corporation ( CTAS ), and Universal Health Services ( UHS ) round out the top five, with RSI levels between 26 and 27. Other notable entries include Dollar General ( DG ), Omega Healthcare Investors ( OHI ), Tenet Healthcare ( THC ), UDR ( UDR ), and Lennar Corporation ( LEN ). All stocks on this top 10 list maintain an RSI below 30, suggesting high selling pressure across sectors including medical facilities, retail, and real estate. The Relative Strength Index is a momentum oscillator that measures the velocity and magnitude of price changes, plotting them on a scale from 0 to 100. RSI compares the magnitude of recent gains to recent losses over a chosen lookback period, typically 14 days. RSI readings of 70 or above are generally considered a signal that a stock may be overbought and potentially poised for a pullback. An RSI below 30 indicates that a stock may be oversold, signaling that intense selling pressure has potentially driven the price below its fair value. Here is the list: Sysco Corporation ( SYY ), Market Cap: $34.11B, RSI: 24 Boston Scientific Corporation ( BSX ), Market Cap: $93.26B, RSI: 25 McCormick & Company, Incorporated ( MKC ), Market Cap: $13.54B, RSI: 26 Cintas Corporation ( CTAS ), Market Cap: $67.66B, RSI: 27 Universal Health Services, Inc. ( UHS ), M...
What you need to know: President Donald Trump will speak at 9 p.m. ET. U.S. gas prices average $4.06 per gallon, according to AAA. Israel continued to strike Tehran on Wednesday. Oil prices have risen to around $100 a barrel. 21 Min Ago Iran's president slams U.S. 'aggression' in letter aimed at American people Iranian President Masoud Pezeshkian looks on as he attends a press conference with Emir...
What you need to know: President Donald Trump will speak at 9 p.m. ET. U.S. gas prices average $4.06 per gallon, according to AAA. Israel continued to strike Tehran on Wednesday. Oil prices have risen to around $100 a barrel. 21 Min Ago Iran's president slams U.S. 'aggression' in letter aimed at American people Iranian President Masoud Pezeshkian looks on as he attends a press conference with Emir of Qatar Sheikh Tamim bin Hamad Al Thani (not pictured), in Tehran, Iran. February 19, 2025. Majid Asgaripour | Via Reuters Iranian President Masoud Pezeshkian , in a letter Wednesday addressed to the American people, defended his country's actions in the war against the U.S. and Israel as "legitimate self-defense" while slamming the "delusions of a foreign aggressor." "The Iranian people harbor no enmity toward other nations, including the people of America, Europe, or neighboring countries," Pezeshkian said in the letter , published by Iranian state media ahead of a scheduled address by President Donald Trump . The leader framed the U.S. for unjust aggression and intervention against Iran spanning decades and argued the current war is damaging America's "global standing." He also accused the U.S. of being a "proxy for Israel" and encouraged Americans to question their government's claims about Iran. — Kevin Breuninger
Bank of America Corp. has a message for Liberty Formula One investors as artificial intelligence fears rattle markets in a volatile macro and geopolitical environment: “Boring is exciting.” The bank upgraded Liberty Formula One to buy from neutral on Wednesday, highlighting the durability of its business and the predictability of revenue growth. Analysts also noted that the owner of the Formula On...
Bank of America Corp. has a message for Liberty Formula One investors as artificial intelligence fears rattle markets in a volatile macro and geopolitical environment: “Boring is exciting.” The bank upgraded Liberty Formula One to buy from neutral on Wednesday, highlighting the durability of its business and the predictability of revenue growth. Analysts also noted that the owner of the Formula One racing series can’t be easily replaced by artificial intelligence. “Amid a volatile macro and geopolitical environment, we believe there is a premium on highly durable and visible business models such as FWONK,” analysts led by Brent Navon wrote in a note. “Moreover, with broader concerns related to AI disintermediation across the media and entertainment ecosystem, we view live sports and FWONK, specifically, as being more insulated from these risks.” Shares in the Formula One owner advanced 0.99% at 3:32 p.m. in New York. Navon maintained his price target of $105 on the stock, which implies upside of 24% from Tuesday’s closing price of $85.02. The company now has 14 buy-equivalent recommendations, three holds and zero sells among analysts tracked by Bloomberg. The company was trading at $91.59 before the war began, but its stock fell after the US bombing began. The war has prompted Formula One to remove races in Bahrain and Saudi Arabia from the April calendar, creating near-term revenue and scheduling gaps. But the dour sentiment around the stock has lifted in recent days and Navon’s upgrade comes as Liberty Formula One is poised to record a second-consecutive weekly advance. The analyst said the war is a one-time disruption that will have no long-term impact to the value of the business. ‘Trophy Asset’ Navon added that Formula One’s predictable business model could lead to something more exciting: a takeover. Formula One is a “trophy asset,” he said, noting that the franchise would generate interest if put up for sale. There has been takeover interest in the past. Saud...
On March 27, the White House announced a “powerful new official mobile app,” calling it “the fastest, most powerful way to stay informed and engaged with the Trump Administration.” While armchair developers and infosec experts have questioned some of the app’s technical design choices, a former FBI special agent uncovered an unusual fact: The small business owner behind the White House app has a s...
On March 27, the White House announced a “powerful new official mobile app,” calling it “the fastest, most powerful way to stay informed and engaged with the Trump Administration.” While armchair developers and infosec experts have questioned some of the app’s technical design choices, a former FBI special agent uncovered an unusual fact: The small business owner behind the White House app has a side hobby as a conspiracy theorist. The White House app was created by 45Press , a company based in Canfield, Ohio, a town of fewer than 8,000 people located roughly halfway between Cleveland and Pittsburgh. (Donald Trump was the 45th president of the United States.) The company’s website describes it as a “design, development, and DevOps agency” and a WordPress VIP Agency Partner; it lists Amazon, NBC, and Sony as past clients. Read full article Comments
In March, the UK announced it would trim its global aid budget and set new priorities in 2027. This has some countries and organizations worried that on top of the US aid cuts, this could be unsurvivable. (Image credit: Luis Tato/AFP)
In March, the UK announced it would trim its global aid budget and set new priorities in 2027. This has some countries and organizations worried that on top of the US aid cuts, this could be unsurvivable. (Image credit: Luis Tato/AFP)